BioSpace News Archive

Drug Development

Clinical Catch-Up: July 12-16

It was a moderately busy mid-summer week for clinical trial news. Here’s a look.

July 16, 2021
·
6 min read
·
Mark Terry
8 Best Cities In The US Offering Biotech Jobs

Biotech jobs are one of the most promising career paths for people who are into life sciences and those who dream of creating change in the world through developing breakthrough medicines and therapeutics.

July 16, 2021
·
5 min read
·
Lorenzo Soliman
Job Trends

GSK’s Planned UK Biotech and Life Sciences Hub to Create 5,000 Jobs

Master planning for the site is slated to begin in 2022 and will reportedly create one of the largest life sciences cluster in Europe.

July 16, 2021
·
2 min read
·
Vanessa Doctor, RN
Policy

FDA Action Alert: Merck, Ligand and Albireo Pharma

There are two PDUFA dates on the U.S. Food and Drug Administration’s calendar for this week. Here’s a look.

July 16, 2021
·
3 min read
·
Mark Terry
Revealing Employee Burnout Signs

Addressing employee burnout signs at an early stage will help build a healthy relationship. It can also help improve the performance. Let’s look at some other benefits.

July 16, 2021
·
5 min read
·
Lorenzo Soliman
Drug Development

Opdivo/Yervoy Combo Fails to Meet Endpoints in Head and Neck Cancer

The randomized, multi-center study called CheckMate -651 evaluates Opdivo 3 mg/kg every two weeks in combination with Yervoy 1mg/kg every six weeks.

July 16, 2021
·
2 min read
·
Vanessa Doctor, RN
Drug Development

Alexion’s Ultomiris Hits Mark in Phase III for Myasthenia Gravis

Boston-based Alexion Pharmaceuticals announced positive topline data from its Phase III trial of Ultomiris (ravulizumab-cwvz) in adults with generalized myasthenia gravis.

July 16, 2021
·
3 min read
·
Mark Terry
Career Advice

Jobs in Virology: Best Opportunities & Tips To Get Hired

The coronavirus disease (COVID-19) pandemic that has ravaged across the globe has demanded more experts in microbiology, particularly jobs in virology.

July 16, 2021
·
5 min read
·
Lorenzo Soliman
Drug Development

Ipsen Bets $363 Million on IRLAB’s Phase II Parkinson’s Drug

The drug, a novel dopamine D3-receptor antagonist, is being evaluated in Phase IIb trials for people with Parkinson’s disease who experience levodopa-induced dyskinesia.

July 16, 2021
·
3 min read
·
Mark Terry
Business

Medtech HeartFlow Joins SPAC Movement, Plans to List on NYSE

Medtech company HeartFlow is heading to the New York Stock Exchange through a merger with special purpose acquisition company, Longview Acquisition Corp. II.

July 16, 2021
·
2 min read
·
Alex Keown